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Genetics is the study of heredity, which means the study of genes and factors related to all aspects of genes. The scientific history
of genetics began with the works of Gregor Mendel in the mid-19th century. Prior to Mendel, genetics was primarily theoretical
whilst, after Mendel, the science of genetics was broadened to include experimental genetics. Developments in all fields of genetics
and genetic technology in the first half of the 20th century provided a basis for the later developments. In the second half of
the 20th century, the molecular background of genetics has become more understandable. Rapid technological advancements,
followed by the completion of Human Genome Project, have contributed a great deal to the knowledge of genetic factors and their
impact on human life and diseases. Currently, more than 1800 disease genes have been identified, more than 2000 genetic tests
have become available, and in conjunction with this at least 350 biotechnology-based products have been released onto the market.
Novel technologies, particularly next generation sequencing, have dramatically accelerated the pace of biological research, while at
the same time increasing expectations. In this paper, a brief summary of genetic history with short explanations of most popular
genetic techniques is given.
1. Introduction
Due to rapid advances in genomic technologies, genetics
analyses have become essential in clinical practice and
research. During the past decade, a great stride has been
made to unravel underlying mechanisms of genetic-related
disorders. Landmarks in genetic history are summarized in
Figure 1. Moreover, genetic testing methods have become
widely accessible and feasible to perform even for small size
laboratories in particular after the completion of Human
Genome Project, which coincided with developments in
computer technology. With the application of genetic test-
ing for personalized medicine, we are at the beginning
of an era that will provide new horizons in human
health.
2. History of Genetic Techniques and
Properties of Methods
2.1. Conventional Cytogenetic Techniques. Looking at the his-
tory in brief, genetics is the term introduced for the study
of genes in organisms. Many early discoveries contributed as
important milestones to evolve the study of genomes as it is
applied today. One of the crucial steps that enabled visualiz-
ing intracellular structures was the invention of the single-
lens optical microscope by Janssen in 1595 [1]. After many
researchers started to make observations with the newly
invented microscope, Hooke has proposed the description of
the “cell” in 1665 [2]. A Swiss botanist Nageli first described
thread-like structures in the nuclei of plant cells in 1840s,
what he called “transitory cytoblasts” which would be defined
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Figure 1: Landmarks in the history of genetics.
as chromosomes later on by Waldeyer in 1888 [3]. After
Charles Darwin published On the Origin of Species by means
of Natural Selection in 1859, Gregor Mendel introduced the
fundamental laws of inheritance in 1865. This was crucial for
understanding that “some characteristics of the organisms
are inherited through genes.” Mendel’s rules were improved
by the experiments of Thomas Hunt Morgan in 1910 who
discovered that genes were responsible for the appearance
of a specific phenotype located on chromosomes. In 1911,
the first genetic map was achieved by mapping the fruit
fly genes. From the 1800s until the middle of the 1900s, it
was not understood that the structure of hereditary genetic
material was responsible for the inheritance of traits fromone
generation to the next. In 1953, Watson and Crick described
the double-stranded, helical, complementary, and antiparallel
model for DNA [4]. They shared Nobel Prize in Medicine
for this major discovery of the structure of DNA in 1962.
In 1966, the genetic code in the DNA was finally discovered
by defining that a codon which is a sequence of adjacent 3
nucleotides codes for the amino acids.The discovery of DNA
and chromosomes paved the way for the rapid improvement
in genetics and establishment of new technologies that have
taken place over the last 50 years.
The first genetic analysis was performed in the field of
cytogenetics. Although it was published that normal human
chromosomenumberwas 48, Tjio andLevan reported in 1956
that the correct number was 46 [5]. After the establishment
of the peripheral leucocyte culture method incorporation
with the fixation and staining methods, it became possible to
identify human chromosome abnormalities associated with
specific congenital defects [6]. Just a few years later, whenTjio
and Levan reported the correct human chromosome number,
several reports identifying numerical chromosome abnor-
malities such as trisomy 21 in Down syndrome, monosomy X
and XXY in two frequent sex chromosomal disorders, Turner
and Klinefelter syndromes, respectively, were published in
1959 [7–9]. After 1966, genetic techniques were performed
not only in the postnatal samples but also in the prenatal
samples, as it was shown that fetal cells derived from amniotic
fluid could be obtained by using an invasive procedure which
is termed as amniocentesis. Steele and Breg reported that
cells cultured from amniotic fluid could be used to determine
the chromosome aberrations in the fetus [10]. However, the
resolution of the chromosomes was not high enough to
determine the structural aberrations in cultured cells which
was improved by the high resolution banding techniques
using synchronized lymphocyte cultures established by Yunis
in 1976 [11].This novel banding technique allowed identifying
the genetic etiology of clinically well-known syndromes such
as Cri-du-Chat and Wolf-Hirschhorn syndromes. Besides
unbalanced aberrations in patients, underlying chromosomal
anomalies in those cases having balanced translocations with
a history of recurrent miscarriages or having a deceased child
with multiple congenital anomalies, have also been described
by the use of the high resolution banding techniques. The
relation between chromosomes and cancer was also estab-
lished by Boveri in 1902. According to Boveri’s somatic
mutation theory, cancer is caused by at least one mutation in
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the cells which causes defect in control of the cell proliferation
and division [12]. He emphasized that the underlying main
reason was abnormal chromosomal changes in a cancer cell.
2.2. Molecular Cytogenetic Techniques. Despite the establish-
ment of high-resolution techniques which enabled reveal-
ing many known or unknown genetic syndromes, several
cases having submicroscopic aberrations that were not vis-
ible at resolution between 500 and 1000 bands remained
undiagnosed. A new technique called fluorescence in situ
hybridization (FISH) was developed in the field of molecular
cytogenetics in 1982 [13]. In this method, cytogenetics and
molecular genetics were bridged. FISH identifies specific
nucleic acid sequences from interphase nuclei or applied on
metaphase chromosomes of [14, 15]. While this technique
has advanced significantly today, it was previously based on
the radioactively labeled ribosomal RNA hybridized to acro-
centric chromosomes followed-up visualizing hybridization
by autoradiography. Several techniques before fluorescence
based techniques such as enzyme-based and gold-based
probe systems were also used in the past [16]. The first
application of FISH was established in 1980, when RNA that
was directly labeled with fluorophore was used as a probe
for specific DNA sequences [17]. Langer et al. developed a
new technique involving the use of a nonradioactive probe for
indirect labeling through nick translation [18]. In later times,
by the development of new fluorescent molecules, which led
to direct and indirect fluorescent labeled probe, binding to
DNA bases improved the protocols of FISH. Chromosome
rearrangements could be detected more easily with increased
resolution of the FISH in both metaphases and interphases
nuclei that could be used for both clinical diagnosis and
research. FISH also provided the option for the simultaneous
use of one ormoreDNAprobes by labeling different colors or
color combinations. Several types of probes can be used for
FISH. Whole-chromosome painting probes, chromosome-
arm painting probes, and centromeric, subtelomeric, and
locus-specific probes are some of the examples which are
available for the detection of specific constitutional and
acquired chromosomal abnormalities. Consequently, a large
number of sophisticated approaches were established based
on the FISH-methods, for example, SKY (spectral karyotyp-
ing FISH) [19], Q-FISH (quantitative FISH) [20], fiber-FISH
[21], heterochromatin-M-FISH [22] (M-FISH multicolor
FISH) [23], COBRA-FISH (combined binary ratio labeling
FISH) [24], cenM-FISH (centromere-specific M-FISH) [25],
and other modified FISH approaches. The most advanced
FISH-based approaches for whole-chromosome analysis are
COBRA-FISH, M-FISH, and SKY FISH. Hybridizing all
24 different human chromosomes with whole-chromosome
painting probes labeled with a combination of 5 different
fluorophores enables visualizing each chromosome with a
specific color. FISH also enabled showing that chromosomes
are compartmentalized into discrete territories in the nucleus
[26]. A correlation between the location and the size and the
gene content of the chromosomes was described. Smaller and
gene-rich chromosomes are generally situated towards the
interior whereas larger and gene-poor chromosomes are gen-
erally situated towards the periphery of the nucleus [27, 28].
With the accurate map of the human genome obtained by
the Human Genome Project, more and more probes from
cloned and mapped segments (cosmids, PACs, BACs, and
YACs) have become available for diagnostic purposes [29].
In light of these studies, several clinical diagnostic FISH tests
have become commercially available. The most remarkable
one is the test for deletion or duplication of the subtelomeric
regions leading to a clinical picture mostly characterized
by multiple congenital anomalies and intellectual disability.
Subtelomeric aberrations are found in approximately 5%
of patients [30–32] and this finding suggested that sub-
microscopic aberrations (i.e., deletions and duplications)
might be present across the genome, particularly in patients
demonstrating similar phenotypes with normal cytogenetic
investigations.
Being time-consuming and expensive to evaluate chro-
mosomal rearrangements in the whole genome by FISH led
to the development of new techniques such as array-based
comparative genomic hybridization [33–35]. Comparative
genomic hybridization (CGH) which is based on competitive
hybridization of amplified tumor DNA and normal DNA
hybridized on normal metaphase slide was first developed
by Kallioniemi et al. in 1992 to detect genomic imbalances
in tumor cells [36]. If we look at the evolution of genetic
technologies, the emergence of new technologies has always
been inevitable due to the necessities revealed by the previous
technologies. Although hybridization-based methods, which
allow screening RNA, DNA, or protein such as northern blot,
southern blot, or western blot, respectively, are widely used,
innovative and powerful microarray hybridization methods
were developed in the 1990s. Instead of hybridizing a labeled
probe to targeted DNA on a slide, with array-CGH, the
patient’s DNA is hybridized to a large number of well-
characterized probes immobilized on a slide. To summarize
briefly, in this method, DNA of the patient is labeled with
a specific color (green) and mixed with exactly the same
amount of DNA of a normal control, which is labeled with a
different color (red). This DNAmixture is then hybridized to
the denaturated probe DNA on the glass and signal intensity
ratios of test over reference are measured. Yellow dye appears
whenboth patient and referenceDNAare equal in proportion
because of the presence of the same amount of red and green
dyes, while regions with copy number losses are visualized
as red and gains are green. This technique permits the
detection of whole genome copy number variation (CNV)
(duplications and deletions) at high resolution [36].
Array-CGH failed to detect the recessive disease genes,
mosaic aneuploidy, uniparental disomy (UPD), or hete-
rochromatic rearrangements. Because of this disadvantage,
it is thought to combine with SNP arrays to improve the
resolution of array-CGH [37]. These arrays have the highest
resolution of all of the available array-based platforms. They
have 10–15 times higher resolutionwhen comparedwith FISH
analysis (5–10 kb) [38]. Combination of array-CGH and SNP
genotyping in a single platform increases the clinical diag-
nostic capability and uncovers the detection of small copy
number variants [39]. In addition, array-based CGH has the
advantage over FISH in the fact that living cells are not needed
to obtain metaphase chromosomes because only DNA is
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needed for analysis.Themajor drawback of array-basedCGH
is that it can only detect unbalanced rearrangements and is
unable to detect balanced aberrations such as chromosome
translocations, inversions, and insertions. However, recently,
a modified array protocol, called translocation CGH (tCGH),
was developed to address recurrent translocation breakpoints
[40].
2.3. Molecular Genetics. Larger genomic changes such as
deletions, duplications, and translocations can be detected
by conventional karyotyping, FISH, or array-CGH methods
but single nucleotide changes cannot be detected by these
techniques. Molecular genetic techniques were rapidly devel-
oped after the establishment of polymerase chain reactions
that enabled generating thousands to millions of copies of a
particular DNA sequence [41]. Mullis and Smith have shared
the 1993 Nobel Prize in Chemistry for their discovery of the
polymerase chain reaction (PCR) technique. Although PCR
was developed only a few decades ago, it has found numerous
basic and clinical applications and is indispensable in today’s
science.
TaqDNApolymerase that was selected the first “Molecule
of the Year” by Journal of Science was a major advantage
in PCR technology [42]. Automation of PCR was greatly
facilitated and simplified the detection of genomicmutations.
PCR was previously used by the following techniques such
as restriction fragment length polymorphism (RFLP), single-
strand confirmation polymorphism (SSCP), and sequencing
based methods. SSCP and RFLP, the most widely used tech-
niques for mutation screening method in genetic diagnostic
laboratories, were not able to detect every mutation, so
development of new methods was needed. If the sequence
of the gene of interest is not known, it may be difficult to
interpret the results of these techniques.The determination of
DNA sequencing enabled identifying the definite nucleotide
changes in the targeted genes. This necessity was overcome
byMaxam and Gilbert introducingMaxam-Gilbert chemical
sequencing technology based on chemical modification of
DNA followed by cleavage at specific bases [43]. Despite
the efficiency of Maxam-Gilbert sequencing method, the
use of hazardous chemical and inability to read long PCR
fragments made this method replaced by Sanger sequencing
that was based on dideoxynucleotide chain termination
[44]. Manual Sanger sequencing method has been improved
by the introduction of first generation of automated DNA
sequencers [45]. Automatization of DNA sequencing enabled
sequencing human genome in a fast and accurate way.
With the advances in the field of molecular genetics,
it became possible to launch the Human Genome Project
to reveal the complete human genome. The programme
was launched in the USA with an effort of the Depart-
ment of Energy and the National Institutes of Health in
collaboration involving 20 groups in 1990. The first draft of
human genome was published in 2001 by The International
Human Genome Sequencing Consortium [46]. This first
report covering 94% of the human genome announced that
the human genome had 30,000–40,000 protein-coding genes
and more than 1.4 million single nucleotide polymorphisms
(SNPs). One day later, in parallel with HGP, Craig Venter
who launched a human genome sequencing project by Celera
Genomics using shot-gun sequencing method published
the whole human genome sequence in Science [47]. The
project was declared to be finished two and a half years
ahead of scheduled time in 2003 coinciding with the 50th
anniversary of the paper in whichWatson and Crick reported
DNA’s double helix [48]. It was reported that 20,000–25,000
genes were present in the human genome covering 93% of
the euchromatic region. Human Genome Project not only
revealed the complete sequence of the human genome but
also led to a huge improvement in the sequencing technology.
Amplification of the gene of interest in the affected individ-
ual(s) enabled revealing mutations associated with specific
monogenic disorders. Although automation of traditional
dideoxy DNA sequencing Sanger method increases the effi-
ciency of DNA sequencing, it was still not cost- and time-
effective. Anew technology calledmassively parallel sequenc-
ing (MPS) erasing these disadvantageswas developed by Lynx
Therapeutics [49]. This technology using reads of multiple
reactions simultaneously and generating large amounts of
sequence data in parallel provided a large impetus for exome
sequencing, whole genome sequencing, and transcriptome
and methylation profiling. This high-throughput technology
that is called next generation sequencing (NGS) technology
reduced the cost of sequencing of a human genome to less
than $1.000. This technology is projected to sequence a
human genome in 1 hour for $100 after new technological
improvements in the near future. NGS technology is widely
used for a variety of clinical and research applications, such
as detection of rare genomic variants by whole genome rese-
quencing or targeted sequencing, transcriptome profiling of
cells, tissues, and organisms, and identification of epigenetic
markers for disease diagnosis. One of the most successful
applications of NGS technology is genome-wide discovery
of causal variants in single gene disorders and complex
genomic landscapes of many diseases. While whole genome
or whole exome sequencing is the most comprehensive strat-
egy in the diagnosis of unknown diseases and identification
of new disease genes, targeted sequencing using selected
panels of genes can reduce the sequencing time and cost
by combining the diseases in the same group or pathway
genes in known clinical pictures such as intellectual disability,
neurometabolic disorders, or malignancies [50].
In addition to cost-effective advantages, sequencing the
small part of the genome allows reducing the number of
variations that in turn reduce the cost and time needed for
data interpretation [51]. Targeted sequencing opened a new
window in the diagnosis of several diseases with unknown
etiology. For instance, it is possible to analyzemore than 4800
genes which were identified in the Human Gene Mutation
Database (HGMD Professional) and the Online Mendelian
Inheritance in Man (OMIM) catalog in a single run for
patients having unknown genetic disorders. Following the
rapid advances in NGS technologies, the role of NGS in rou-
tine clinical practice will increase exponentially. Noninvasive
prenatal diagnosis by using NGS is another application of
this new technology.Themost important step in the prenatal
diagnostic procedures is obtaining fetal material to evaluate
genetic condition. For years, invasive and noninvasive tests
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have been used to assess the fetal health, particularly chro-
mosomal abnormalities, during the pregnancy. Noninvasive
tests measure epiphenomena, which does not analyze the
pathology underlying the clinical picture of interest. Their
sensitivity and specificity have not also reached the expected
level despite several studies. On the other hand, invasive tests
have been found to be associated with significant risks for
both the mother and fetus. The identification of cell-free
fetal DNA in maternal circulation and analyzing this fetal
material by using NGS opened up a new horizon in the
field of reproductive medical care. Despite main advantages
of NGS technology, the researchers and clinicians still have
many concerns about the implementation of NGS in practice
[52]. The interpretation of huge amount of data obtained
by NGS technology, billing and insurance issues, duration
and content of consent process, and disclosure of incidental
findings and variants of unknown significance were the main
challenges related to offering this technology [53].
Approximately 10 years ago, karyotyping was the gold
standard in patients with intellectual disability but array-
CGH analysis has become the first line diagnostic test
replacing karyotyping and FISH nowadays. As evident from
this example, approaches to the genetic-related diseases could
change in parallel with the advances in technology and
science. “Philadelphia chromosome” is one of the oldest
evolutionary examples of personalized medicine by revealing
the etiological factor and the treatment options of a disease
step by step by using the genetic analysis as the improvements
in the genetic techniques were established. In 1960, a small
chromosome called Philadelphia chromosome was identified
to be the cause of the chronic myeloid leukaemia (CML). It
was shown in 1973 by the chromosome banding technique
that this chromosome was a result of a translocation between
chromosomes 9 and 22 [54, 55]. It took more than 10 years
to identify the fusion gene BCR/ABL (breakpoint cluster
region and v-abl Abelson murine leukaemia viral oncogene
homologue) through the improvements of the molecular
techniques [56]. The following studies revealed that this
fusion gene resulted in activation of a tyrosine kinase, which
led to the discovery of a tyrosine kinase inhibitor drug
Gleevec that was shown to be a highly successful treatment
for CML [57].
Genetic test that will be used in the diagnosis should be
chosen very carefully, which might not be the newest or the
most sophisticated one. Sometimes only a karyotype could
be enough to identify the genetic condition in the patient
instead of more complicated array-CGH or NGS methods.
As the technology in genetics rapidly evolves, new insights in
terms of data interpretation and genetic counseling including
pretest counseling, return of results, and posttest counseling
need to be considered. Databases and consortium reports
regarding the experiences of the clinicians and geneticists are
crucial for integration of genomics into clinical practice.
3. Conclusion
If the developments in genetics and computer technologies
continue to progress at their current speed, history has shown
us we can look forward to some amazing developments in
human life in the very near future. Some realistic scenarios of
human life in the future could even see us carrying identity
cards, which include our genome characteristics, rather than
the format we are currently using. Gene corrections, cloned
individuals and organs, and even genetic-based techniques as
a primary laboratory analysis in almost all human diseases
for a clinician will no longer be a dream. We have come to
the point nowadays where genetic testing is commercially
available; the individual now has the possible means to
access this delicate information named as direct to consumer
(DTC) genetic testing. Contrary to the traditional hospital
or physician based testing, accessing an individual’s genetic
information without medical or specialized interpretation
has gradually been finding a place in our daily lives. Today,
more than 25 companies, from all over the world, offer DTC
service to the public. Serious concerns, however, regarding
the use of this kind of service, have been raised in terms
of misleading and incidental results derived from unproven
or invalidated data. Moreover, there is also a significant
risk for unauthorized use of sensitive genetic information
by big business, particularly in the fields such as health
insurance. On the other hand, DTC does provide early
awareness of genetic diseases and thereby offers individuals
the opportunity to play an active role in their own health care.
The issue at stake here leads us to the same difficult medical
ethics dilemma: patient autonomy and right to know one’s
genetic composition versus nonmaleficence.
To conclude, in parallel with the rapid developments
in the field of genetic technologies, ethical and legal issues
regarding the implementation of those technologies need to
be addressed. Because use of personal genetic information
looks certain to directly impact our daily lives in the near
future, protocols need to be discussed in detail, with guide-
lines provided and updated regularly as part of a regulated
multidisciplinary approach.
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